Yoland Antill is a medical oncologist and specialist in Hereditary Cancer medicine. She has more than 15 years experience in the management of breast and gynaecological cancers. She holds public hospital appointments at Frankston Hospital and Royal Melbourne Hospital together with her private practice at Cabrini Health in Melbourne. She is a lead investigator or co-investigator on multiple national and international studies focused on the management of breast and gynaecological cancers and in hereditary cancer medicine, including the management of urogenital symptoms associated with Breast Cancer treatments.

Caroline Baker is Head of Breast Surgery at St Vincent’s Public Hospital Melbourne, after having serving for 6 years as Director of Breast Services at the Olivia Newton John Cancer and Wellness Centre. She is also Chief Surgeon to St Vincent’s Breast Screen . She gained her FRACS in 1994, then spent 5 years in The UK, subspecialising in the emerging field of breast surgery under the mentorship Mr. Mark Kissin and at The Royal Marsden Hospital in London.
Caroline is a foundation member of BreastSurgANZ, a longterm member of the Australasian Society of Breast Diseases and has been a member of BCT/ANZBCTG since 1998. Caroline regularly teaches students, junior doctors and registrars through The University of Melbourne, lymphoedema practitioners, nurses and volunteers within the Breast Cancer Network of Australia. She has a special interest in neoadjuvant therapy, lymphedema prevention and multidisciplinary care.

Alexandra Barratt (MBBS, MPH, PhD) is an epidemiologist and Professor of Public Health at the University of Sydney. She has participated in a wide range of health services research over the last 25 years, including projects on screening for breast and prostate cancer. Currently, she is a lead investigator of Wiser Healthcare, a research collaboration to reduce overdiagnosis and overtreatment. She is a member of the Scientific Committee for Preventing Overdiagnosis, an international collaboration working to wind back the harms of Too Much Medicine. In 2006 and 2007 she won back-to-back Australian Museum Eureka prizes and is an Australian Museum Eureka Prize Ambassador.

Fran Boyle is a Medical Oncologist at North Sydney’s Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She chairs the Board of the ANZ Breast Cancer Trials Group and has been involved in all facets of clinical trial research in breast cancer.

Dr Alexis Butler has worked as a GP for many years in the UK and Melbourne and is also the GP Liaison Physician at Peter MacCallum Cancer Centre. A core component of her work is improving patient outcomes and experience through optimising collaboration between primary care and hospitals.
Alexis has also worked as a GP education consultant for The Royal Children’s hospital and The Royal Victorian Eye and Ear hospital creating practical face to face, on-line and virtual classrooms programs for primary care. Currently she is also at Victorian Cytology Services involved in research and primary care education on the new national cervical screening program.

Ian Campbell is currently a Consultant Surgeon at Waikato Hospital and an Associate Professor with the Waikato Clinical School, University of Auckland Medical School. He has subspecialised in the management of breast cancer over the last 25 years and has Chaired a number of national committees on breast cancer management and standards of care in NZ, including the NZ Guidelines Group: Management of Early Breast Cancer published by the NZ Ministry of Health in 2009, and the National Breast Cancer Work Group responsible for developing Standards of Service Provision for Breast Cancer, published 2013.
He is very actively involved in clinical research across the spectrum from prevention to better treatment and quality of life. A particular interest is in sentinel node biopsy and management of the axilla, and he is a member of the SNAC Trial Executive and Co-Chair of the SNAC2 Trial. Ian is a long standing member of the ANZ Breast Cancer Trials Group Scientific Advisory Committee, previous Chair of the Local therapy subcommittee, and previous NZ member on the ANZBCTG Board.

Dr. Caudle is an associate professor of breast surgical oncology at the University of Texas MD Anderson Cancer Center. Her research has centered on the surgical management of nodal disease in breast cancer, specifically the development of targeted axillary dissection, a novel surgical technique that improves axillary node staging after neoadjuvant chemotherapy. She also has research interests focusing on improving quality in breast cancer surgery and methods for improving dissemination and implementation of clinical trial data.

Professor Chan graduated from the University of Melbourne, and subsequently obtained her Fellowship in Medical Oncology and a Masters of Medicine in Palliative Care.
She worked in the area of cancer genetics in City Hospital, Nottingham and breast cancer in Princess Margaret Hospital, Toronto. She has worked solely in the area of breast cancer for nearly 20 years and has a strong commitment to breast cancer research, having personally recruited over 1100 patients to clinical trials and has served on the academic steering committee of three international studies. She has authored >100 breast cancer publications in journals including New England Journal of Medicine, Lancet Oncology and Journal of Clinical Oncology; and has been a accessor for UK NHS, young investigator and NHMRC grants.
She is an adjunct professor in the school of medicine at Curtin University and was a founding member of Breast Cancer Research Centre-WA. She established the Helen Sewell Breast Cancer Tumour Bank which has led to the collection of over 3000 annotated breast cancer samples for future research. She is currently the Director of the Breast Clinic Trials Unit of the Breast Cancer Research Centre-WA, based at Hollywood Private Hospital in Perth, Western Australia.
She was awarded the Western Australia of Year Award in Professions 2016 for her contribution in the field of science at a state, national and international level and was a finalist for Australian of the Year in 2017.

Michael Chao is a radiation oncologist specializing in breast and prostate cancers from the University of Melbourne, the Olivia Newton John Cancer and Wellness Centre (ONJCWC) and Genesis Care Victoria (GCV). He is actively involved in both investigator initiated and multicenter studies at the ONJCWC and GVC. His main areas of interest include the use of preoperative radiotherapy in locally advanced breast cancer before definitive mastectomy and autologous breast reconstruction, the use of silicone gels to diminish the incidence of radiation dermatitis in patients undergoing breast/chest wall radiotherapy and the effect of low dose radiation on myocardial function. He is also passionate about the use of high technology such as volumetric arc therapy in breast cancer radiotherapy.

Prof. Louis Chow is Executive Director of the Organization for Oncology and Translational Research in Hong Kong; a distinguished professor of Macau Science Technology; a Medical Director of the Comprehensive Centre for Breast Diseases at the UNIMED Medical Institute in Hong Kong, an honorary professor of the Third Military Medical University; an honorary professor at Ningxia Medical College School of Clinical Medicine in Ningxia, China; an honorary professor at Tohoku University in Sendai, Japan; visiting professor at Wuhan University of Science and Technology; and an honorary consultant of Kiang Wu Hospital in Macau. Professor Chow was the immediate past honorary clinical professor of the clinical trials centre at The University of Hong Kong, past president of the Asian Breast Cancer Society, and former honorary secretary of The Hong Kong Academy of Medicine.
Professor Chow is an expert in cancer research and has obtained a patent on a mouse cell line derived from human malignant cystosarcoma phylloides. In the past few years, he has obtained various research and professional grants for cancer research purposes in the university and contributed as Principal Investigator/Co-investigator of several international clinical trials. Professor Chow has published more than 190 articles in peer-reviewed journals. His key research interests are breast cancer molecular therapy, chemoresistance, chemoprevention and translational research in breast cancer.
Professor Chow was awarded The Kim Hyun-Jib Breast Cancer Research Memorial Award in 2012

Dr Boon H Chua is Professor of Medicine at UNSW Sydney; Consultant Radiation Oncologist, Director of Cancer and Haematology Services, and Medical Co-Director of the Program of Neurosciences, Cancer Services, Rehabilitation, Intensive Care, Radiology and Nuclear Medicine at the Prince of Wales Hospital in Sydney.
With clinical and academic subspecialisation in breast cancer, Dr Chua leads a national and international program of competitive grant-funded oncology research in collaboration with cooperative clinical trials groups worldwide. She also holds leadership positions in a diverse range of national and international organisations including Executive Board member of Breast International Group, Education Faculty member of European Society of Medical Oncology, Scientific Advisory Committee Executive of Breast Cancer Trials-ANZ, and Breast Subspecialty Group Chair of Trans Tasman Radiation Oncology Group.
Dr Chua was a senior clinical leader for redevelopment of Peter MacCallum Cancer Centre where she was Staff Specialist until November 2016. As Chair and Principal Council Representative of the RANZCR Post-Fellowship Education Committee, Dr Chua led development and implementation of the national program of continuing professional development in Radiation Oncology.

Jennifer Chynoweth has worked as an executive in the Australian Public Service for over two decades, working on health and social policy. She is currently leading initiatives at Cancer Australia that aim to improve lung, breast and gynaecological cancer outcomes, and address unwarranted variations in cancer outcomes and experiences for Aboriginal and Torres Strait Islander people.
Jennifer has sponsored the expansion of Aboriginal and Torres Strait Islander cancer control policy at Cancer Australia, notably through publication of the National Aboriginal and Torres Strait Islander Cancer Framework, establishment of the Leadership Group on Aboriginal and Torres Strait Islander Cancer Control and the development of the Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer.

Dr. David Clouston is an Anatomical Pathologist at Tissupath which is a specialist pathology practice in Melbourne, and specialises in breast pathology. David has a particular interest in tumour diagnosis and has presented locally and nationally on topics in breast pathology. He is a member of the BreastScreen Victoria Clinical Reference Group.

Associate Professor Prue Cormie is an Accredited Exercise Physiologist whose research and clinical work focuses on the role of exercise in the management of cancer. Her track record includes over $3 million in competitive research grant funding and over 70 refereed publications and book chapters. Prue has produced influential research exploring the efficacy of targeted exercise prescriptions in counteracting significant side effects of cancer and cancer treatments. Prue is the inaugural Chair of the Clinical Oncology Society of Australia Exercise Cancer Group and leads the Exercise and Sports Science Australia Cancer Special Interest Group. A core component of her work is invested to translating research into practice for meaningful improvements in health care services for people with cancer.

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. Since 2003, he has worked in the Department of Medical Oncology at the Hospital Vall d’ Hebron, Barcelona, where he is Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés is Head of the Breast Cancer Unit and the Melanoma Unit.
In addition, he has two masters’ degree: “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr. Cortes is the author of more than 100 publications, especially about breast tumours and new drugs and more than 250 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), a member of the Scientific Committee of the European Society of Medical Oncology and the Scientific Committee of SOLTI group.

Jack Cuzick is a director of Wolfson Institute of Preventive Medicine in London and a head of its Centre for Cancer Prevention. He is John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He has been awarded CBE in Jan 2017, he is a Fellow of the Royal Society, Academy of Medical Sciences and the Royal Statistical Society.

Sarah-Jane Dawson
Associate Professor Sarah-Jane Dawson is a clinician-scientist. She obtained her medical degree from the University of Melbourne in 1998, and trained as a medical oncologist in Melbourne, Australia. She completed her PhD at the University of Cambridge, UK. Following postdoctoral studies at the Cambridge Research Institute, she returned to Melbourne in 2014 to head the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre. Her current research interests are focused on the development of noninvasive blood-based biomarkers (‘liquid biopsies’) for clinical application, including early detection, risk stratification and disease monitoring in cancer management.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Center Singapore and is Chief of the Breast Medical Oncology Service.
She is also an Associate Professor at Duke-National University Singapore Medical School. Dr Dent received her medical degree in 2000 from McMaster University in Hamilton, Canada, and obtained her Master of Science degree in clinical epidemiology and biostatistics from the University of Toronto, Canada. She obtained her internal medicine and medical oncology training at the University of Toronto, Canada.
Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer. She serves on a number of scientific committees at ASCO, ESMO and ESMO Asia.

Professor Mitch Dowsett, FMedSci, PhD, is Head of the Centre for Molecular Pathology at the Royal Marsden Hospital; Professor of Biochemical Endocrinology at the Institute of Cancer Research; and Professor of Translational Research in the Toby Robins Breast Cancer Research Centre, London.

Professor Dowsett’s research focuses almost exclusively on breast cancer and predominantly on hormonal aspects of the disease and biomarkers of response with a research team of about 24 investigators. He was closely involved with the clinical development of aromatase inhibitors and in the creation of national and international standards for steroid receptor and HER2 analyses (ASCO/CAP Guidelines Steering Committees). He co-chairs the International Working Party for Ki67 in Breast Cancer. He was the founding chairman of the UK NCRI Translational Research (subsequently Biomarker and Imaging) Clinical Study Group.

He has authored over 600 published papers related to breast cancer, and given numerous named lectures including the 2007 William L McGuire Memorial Lecture and the prestigious Susan G. Komen Brinker Award lecture For Scientific Distinction at the San Antonio Breast Cancer Symposium (December 2014). He served 7 years on the Executive Board of the Breast International Group (BIG) and sits on the Executive/Steering Committees of several clinical trials. He has been a NCRI Senior Clinical Investigator since 2009. In 2013 he was appointed as a Fellow of the Academy of Medical Sciences. In January 2018 he was the inaugural Chair of the 1st UK Interdisciplinary Breast Cancer Symposium.

Elisabeth Elder is a specialist breast surgeon at the Westmead Breast Cancer Institute and Clinical Associate Professor at the University of Sydney, with a special interest in oncoplastic and reconstructive surgery. She is involved in numerous research projects and clinical trials within the Westmead Breast Cancer Research Collaborative. She graduated from the Karolinska Institute in Sweden in 1992, where she also completed her general surgery training and a PhD in tumour biology in 2002. She is chair of the oncoplastic committee of Breast Surgeon in Australia and New Zealand and council member of Breast Surgeons International as well as vice President of ASBD. She regularly participates in breast cancer education for medical professionals, students as well as patient groups and the broader community.

Professor Jacinta Elston
Pro Vice-Chancellor (Indigenous), Portfolio of the Deputy Vice-Chancellor and Vice-President (Education) Monash University
Chair of Cancer Australia’s Leadership Group on Aboriginal and Torres Strait Islander Cancer Control
Professor Jacinta Elston is an Aboriginal woman from Townsville in North Queensland.
Professor Elston is the Pro Vice-Chancellor (Indigenous) at Monash University and is the Chair of Cancer Australia’s Leadership Group on Aboriginal and Torres Strait Islander Cancer Control. She is a former member of the Cancer Australia Advisory Council and has served as a member on the NHMRC Research Committee.
Professor Elston holds a Master of Public Health & Tropical Medicine.

Laura Esserman

Education

1977 AB, Harvard University, Cambridge, MA
1983 MD, Stanford University, School of Medicine, Stanford, CA
1993 MBA, Stanford University, School of Business, Stanford, CA

Training
1983-85 Resident in General Surgery Stanford University School of Medicine, Stanford, CA
1985-88 Postdoctoral Fellow, Department of Medicine, Division of Oncology Stanford University School of Medicine, Stanford, CA
1988-90 Resident, General Surgery Stanford University School of Medicine, Stanford, CA
1990-91 Chief Resident, General Surgery, Stanford University School of Medicine, Stanford, CA

Licenses and Certifications
04/92 Board Certification, General Surgery
State of California, G 053346
State of Hawaii, 6864

Positions

UCSF Appointments

Current Appointment:

Professor of Surgery and Radiology
Director, UCSF Carol Franc Buck Breast Care Center
Affiliate Faculty Appointments: Institute for Health Policy Studies, Biomedical Informatics, QB3 Clinical Associate

Dr Jill Evans has been the Clinical Director of Monash BreastScreen for seven years and Designated Radiologist of Monash BreastScreen for 25 years. Dr Evans was appointed the State Radiologist for BreastScreen Victoria in 2011.
Jill has served on many national committees including, as Radiologist member of the NQMC since 2016 and as a member of the Clinical Advisory Committee since its inception in 2014, and is currently a member of the Breast Screening Technical Reference Group. She has been a member of the Breast Imaging Advisory Committee of the RANZCR since 2012.
Within BreastScreen Victoria, Dr Evans chairs the Radiology Quality Group and is a member of the Victorian State Quality Committee, Research Committee, Quality Improvement Committee and Clinical Reference Group.
Jill has made significant contributions to the field of breast screening through participation in research and presenting at national and international conferences.

Gelareh Farshid MBBS, MD, MPH, FRCPA, FFSc (RCPA), GAICD
Prof Gelareh Farshid is a surgical pathologist with expertise in population based mammographic screening. She is a Senior Consultant Pathologist at South Australian Pathology. Gelareh’s research focus includes optimizing the assessment outcomes for women with screen detected breast lesions and the accuracy of biomarker evaluation. Gelareh serves on several international and national pathology and screening committees.

Stephen Fox is Director of Pathology at the Peter MacCallum Cancer Centre and Professorial Fellow at the University of Melbourne. He holds Honours degree and Medical degrees from the University of Bristol, UK and a DPhil in Medicine from the University of Oxford. He has Fellowships of both the Royal College of Pathologists Australasia (RCPA) and UK and is also a Founding Fellow of the Faculty of Science (RCPA). He is an NHMRC Practioner Fellow and a Fellow of the Australian Academy of Health and Medical Sciences. His current focus is development of diagnostic predictive markers of response to therapies in several tumour types using protein and DNA-based assays.

Prudence Francis commenced Medical Oncology training in Australia and subsequently completed training in the USA. She spent 4 years at Memorial Sloan-Kettering Cancer Center in New York. In 1994 she was appointed as a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne. Since 2003 she has been the Clinical Lead for Breast Medical Oncology at Peter MacCallum. She is Chair of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (ANZ BCTG). She is a member of the Scientific Committee of the International Breast Cancer Study Group (IBCSG). She is a panel member on the Advanced Breast Cancer (ABC) International Consensus Panel and the St Gallen International Consensus Panel for Primary Therapy of Early Breast Cancer. As a clinician researcher she has focused much of her research on randomized breast cancer trials.

Ian Freckelton is a Queen’s Counsel in full-time practice as a barrister throughout Australia. He is a Professor of Law and Psychiatry at the University of Melbourne where he is the co-director of the postgraduate Health Law Program, and an Adjunct Professor of Forensic Medicine at Monash University. He is a judge of the Supreme Court of Nauru and a member of Victoria’s Coronial Council and Mental Health Tribunal, and was the Commissioner in charge of the Victorian Law Reform Commission’s reference on Medicinal Cannabis. He is the Editor of the Journal of Law and Medicine and the Editor-in-Chief of Psychiatry, Psychology and Law. He is the author of more than 40 books and over 600 peer reviewed articles and chapters of books.

James French is the head of breast surgery at the Westmead Breast Cancer Institute and a clinical lecturer at Sydney University. He has a particular interest in the use of mammoplasty techniques in breast conserving surgery ensuring both good cancer and aesthetic outcomes. He also specialises in nipple sparing mastectomy combined with immediate direct to implant pre pectoral based reconstruction. James is an enthusiastic teacher of surgical trainees and fellows and has contributed to over 40 peer reviewed papers.

Dr. Sarah Hardcastle is a Senior Research Fellow based in the Health Psychology and Behavioural Medicine Research group at Curtin University, Australia. Her main area of research is the application of application of motivational theories to understand health behaviour change, particularly in relation to physical activity and lifestyle. The main focus of her research is to understand behaviour change and the application of interventions to change health behaviours. Sarah’s primary interests are the promotion of physical activity to prevent or manage chronic illness and cardiovascular disease. She is currently leading several trials using wearable technology and health coaching to increase physical activity in cancer survivors. She also has particular expertise in the application of Motivational Interviewing to promote health behavior change in healthcare settings.

Associate Professor Marion Harris is a medical oncologist and cancer geneticist who works at Monash Health in Melbourne. She is Director of the Familial Cancer Centre at Monash Health and has an academic appointment at Monash University . She is active in clinical research in familial cancer, breast and gastrointestinal malignancies especially pancreatic cancer.

Chris Hart first developed an interest in breast cancer during his specialist training in medical oncology, which was completed in 2013. From there he went on to do a two year fellowship in Breast Cancer translational research at Prato Hospital in Italy, during which time he was involved in both preclinical studies and reviews of the clinical management of breast cancer, including participating in updating guidelines for Breast Units across Europe. He now works as a full-time Medical Oncologist at St Vincent’s Hospital Melbourne, and is involved in clinical trials.

Martha Hickey is Professor of Obstetrics and Gynaecology at the University of Melbourne and an NHMRC Practitioner Fellow. She initially trained and worked as a Clinical Psychologist, and then studied medicine at Bristol University, She was awarded Doctorate in Reproductive Health from Bristol University and moved to Australia from Imperial College London in 2001. She is a member of the World Health Organisation Human Reproduction Program Research Panel and Senior Editor for the Cochrane Collaboration. Professor Hickey has clinical and research interests in menopause, and in particular the management of menopause after cancer.

Dennis R. Holmes, M.D. is the Associate Professor of Surgery at the John Wayne Cancer Institute in Santa Monica, California. As a dedicated breast surgeon, Dr. Holmes has dedicated his career to breast cancer treatment innovation through clinical research. He was an early investigator in the TARGIT-A clinical trial that evaluated the effectiveness of targeted intraoperative radiotherapy as an alternative to conventional whole breast radiotherapy. He currently serves as Co-Principal Investigator of the TARGIT U.S. Registry Trial and as President of the TARGIT Collaborative Group, a national organization of surgeons, radiation oncologists, and physicists committed to improving cancer patient care through education, patient advocacy, mentorship, and collaborative research. Dr. Holmes also serves as national principal investigator of the FROST (Cryoablation) Trial. Dr. Holmes currently holds the position of Program Chair of the upcoming 2019 American Society of Breast Surgeons 20th Annual Meeting; co-chair of the Oncoplastic Surgery Committee; chair of the Video Library Subcommittee; and chaired the development of the society’s performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer.

Reshma Jagsi, M.D., D.Phil., is Professor, Deputy Chair, and Residency Program Director in the Department of Radiation Oncology and Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan. She graduated first in her class from Harvard College and then pursued her medical training at Harvard Medical School. She also served as a fellow in the Center for Ethics at Harvard University and completed her doctorate in Social Policy at Oxford University as a Marshall Scholar. An active clinical trialist and health services researcher, Dr. Jagsi’s medical research focuses on improving the quality of care received by breast cancer patients, both by advancing the ways in which breast cancer is treated with radiation and by advancing the understanding of patient decision-making, cost, and access to appropriate care. Her social scientific research includes research into issues of bioethics arising from cancer care and research regarding gender issues, including studies of women’s representation in the medical profession. She is the author of over 200 articles in peer-reviewed journals, and her research is actively funded by multiple independent grants from the National Institutes of Health, the Doris Duke Foundation, and other philanthropic foundations. She serves on the Steering Committee of the AAMC’s Group on Women in Medicine in Science, the Board of Directors of the American Society of Clinical Oncology, the Steering Committee of the Early Breast Cancer Trialists Collaborative Group, the editorial boards of the Journal of Clinical Oncology and JAMA Oncology, and numerous other influential national professional committees. Her contributions have been recognized with her election to the American Society of Clinical Investigation.

Assoc Prof Paul A James is a Clinical Geneticist from Melbourne. He is the director of the Parkville Familial Cancer Centre (Royal Melbourne Hospital and Peter MacCallum Cancer Centre) and Head of Clinical Genetics in the Department of Genomic Medicine (RMH). He leads a program of clinical research including discovery and translational projects emphasising familial cancer and the genetics of inherited cardiac disorders, and is a group leader in Familial Cancer research at Peter MacCallum.

Prof. Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at the Royal Marsden. He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997. He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II / III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 230 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of several scientific committees and advisory boards, a Faculty Member at the American Society for Clinical Oncology, the Deputy-Editor of the international journal ‘Breast Cancer Research’, and a former Trustee of the UK charity ‘Breast Cancer Campaign’ having also been Chairman of their Scientific Advisory Board.

Virginia Kaklamani, MD DSc
Dr. Virginia G. Kaklamani is professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio and is the leader of the Breast Cancer Program at the Cancer Therapy & Research Center. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology/oncology at Northwestern University. She also received a master of science degree in Clinical Investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of Northwestern’s cancer genetics program. Her research interests include studying high risk families and identifying genetic mutations that are associated with an increased risk for breast, colon and prostate cancer. She has identified several genetic mutations related to obesity that increase the risk of breast cancer. Dr. Kaklamani is a clinical investigator with expertise in designing clinical trials with targeted agents.

Dr Minjae Lah is a dedicated Radiation Oncologist who holds her expertise in breast and lung cancer management. She completed her undergraduate medicine and residency training in Queensland. She gained further experience in Sydney to achieve her fellowship in Radiation Oncology. Since 2004, she has been practicing in Brisbane.
In addition to her interests in innovative techniques in radiotherapy, she is a passionate supporter of multidisciplinary care in clinical decision making and delivery of cancer care. For over a decade, she has been involved in graduate medicine, Radiation Oncology and continued medical education trainings in her academic and clinical roles. She is the current Research Chair at Genesis CancerCare Queensland, leading her team in clinical research for cancer.

Sunil Lakhani is Professor and Head, Discipline of Molecular & Cellular Pathology, The School of Medicine, Head of the Breast Group, The University of Queensland Centre for Clinical Research (UQCCR) and Executive Director Research, Pathology Queensland,
His research team comprising of both scientists and practicing clinicians ensures a translational focus to the research portfolio. His current interests include lobular carcinoma and its variants, tumours with a basal phenotype and mechanisms and therapeutic development of brain and distant metastases. He is a series editor for the WHO Tumour Classification Books and volume editor for the Breast Tumour Classification.

A/Prof Elgene Lim is a medical oncologist at The Kinghorn Cancer Centre, St Vincent’s Hospital, and leads the Connie Johnson Breast Cancer Research Group at the Garvan Institute of Medical Research. He obtained his training at the University of Melbourne, Walter& Eliza Hall of Medical Research, and Dana-Farber Cancer Institute. He is the inaugural National Breast Cancer Foundation Endowed Chair and a clinical academic at the UNSW medical school. His research team performs clinically focused laboratory research, utilizing patient-derived breast tumour xenografts for the evaluation of novel therapies. A major focus of his group is on overcoming resistance to currently used endocrine therapies. His research is funded through the National Breast Cancer Foundation, Cancer Australia, Cancer Council of NSW, National Health and Medical Research Council, Love Your Sister, the Garvan and St Vincent’s Clinic Foundation, and the ANZ Breast Cancer Trialist Group.

Geoff Lindeman, a clinician-scientist, is Joint Head of the Stem Cells and Cancer Division at the Walter and Eliza Hall Institute and a medical oncologist at The Peter Mac and Royal Melbourne Hospital. His laboratory is studying molecular regulators of normal mammary gland development and cancer, with a particular interest in understanding how mammary stem cells and their progeny contribute to the mammary gland development and cancer. The recent discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers has led to an international prevention study, BRCA-P. His laboratory is also using patient derived xenograft and tumour organoid models to test promising anti-cancer agents. This work has led to early phase studies of the BCL-2 inhibitor venetoclax in breast cancer.

Jocelyn Lippey is a breast surgeon from Melbourne, Victoria. Having completed her general surgery fellowship through the Austin hosptial she underwent post fellowship training through Breast Surg ANZ at Peter MacCallum Cancer Centre in 2015 and Perth in 2016 working at Royal Perth and Fiona Stanley Hospitals.
She is a current recipient of an NBCF practitioners grant to develop a risk communication tool as part of a risk-stratified Breast screening trial as well as doing clinical work at The Northern hospital in Melbourne.
Her interests include research into breast cancer, risk communication, tailored breast screening and DCIS as well as oncoplastic and reconstructive surgery.

AProf Lara Lipton is a medical oncologist working in the VCCC Family Cancer Clinic and the Cabrini Family cancer Clinic as well as in private and public practice. She undertook a PhD in Cancer Genetics at Cancer Research UK and since returning to Australia has worked at Western Health, The Royal Melbourne Hospital and Peter MacCallum cancer Centre. She is part of the Brightways Breast Cancer Program at Cabrini and is active in clinical research in breast and GI malignancies.

Associate Professor Sherene Loi is a medical oncologist specialised in the treatment of breast cancer and head of the Translational Breast Cancer Genomics laboratory at the Peter MacCallum Cancer Centre, Melbourne, Australia. She completed her medical oncology training in Melbourne, Australia in 2004 and then completed her PhD and 4 years of post-doctoral experience with Drs Christos Sotiriou and Martine Piccart in Brussels, Belgium. There she gained significant experience in the use of genomic technologies, drug development, clinical trial conduct and design.

The aims of her lab are to understand the drivers and predictors of prognosis in breast cancer using high-throughput genomic technologies as well as using in vitro and in vivo preclinical models. Ultimately, the aim of her lab is to translate such findings into therapeutic approaches for breast cancer patients. Recently, she has developed a keen interest in immunotherapeutic approaches, as she was first to report on the positive prognostic value of tumor infiltrating lymphocytes in triple negative and HER2-positive breast cancer. Further preclinical work has supported the concept that immune approaches could be beneficial in these breast cancer subtypes. She also plays a role in many breast cancer clinical trials that evaluate targeted approaches as well as immunotherapies.

Cindy Mak is a breast surgeon who trained at the Edinburgh Breast Unit and in Sydney. She is the current Director of Breast Services at Chris O’Brien Lifehouse and Royal Prince Alfred Hospital in Sydney and is involved with the oncoplastic subcommittee of BreastSurgANZ.

Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.

Nicole McCarthy
Associate Professor Nicole McCarthy MBBS (Hons), MHSc, FRACP is a Consultant Medical Oncologist at Icon Cancer Care at the Wesley Medical Centre and Wesley Hospital in Brisbane and her academic appointment is with the School of Medicine, University of Queensland . She completed a 3 year Medical oncology fellowship at the National Cancer Institute, Bethesda MD and a Masters in Health Sciences in Clinical Trial Design through Duke University. She is an academic clinician and her clinical practice and translational research focuses on the multifaceted aspects of breast cancer care and management. She led the Breast Cancer Clinical trials unit at the Royal Brisbane and Women’s Hospital for over 10 years and now provides leadership for the breast cancer clinical trials component of ICON Research Foundation Clinical Trials Unit, the largest national private oncology provider. A/Prof McCarthy is considered an opinion leader in breast cancer management at a local and national level and her own investigator-initiated clinical trials have been incorporating new agents into neoadjuvant breast cancer treatment. A/Prof McCarthy has been the Chair of the Systemic Therapy Subcommittee of the ANZ Breast Cancer Trials Group Scientific Advisory Committee (SAC) since 2007 and a member of the SAC since 2004. She has been the Australian Principal Investigator on several international clinical trials. A/Prof McCarthy has been a member of a number of national breast cancer guideline panels and has played a close role with breast cancer consumer advocacy groups.

Dr Kate Moodie

Current Employment details
Radiologist & Molecular Imaging Specialist, Cancer Imaging Department,
Peter MacCallum Cancer Centre. Full Time.
Peter MacCallum Cancer Centre
2006: Diagnostic Imaging Radiology Fellow
2007 – current: Radiologist & Molecular Imaging Specialist
Additional roles at Peter Mac;
– Modality Lead Breast Imaging and Ultrasound
– Breast MultiDisciplinary Lead for Peter Mac
– Quality Committee Cancer Imaging
Fellowships:
-Breast Imaging Canterbury BreastCare 2003
-Nuclear Medicine Fellowship MIA Victoria 2004
-Nuclear Medicine Fellowship Alfred Hospital Melbourne 2005
-Radiology Fellowship Peter MacCallum Cancer Centre 2006
Current/ Active Research at Peter MacCallum Cancer Centre
-A randomised trial comparing FDG-PET/CT with Conventional Imaging
(CT and WBBS) with respect to their first-line utility in the staging or
restaging of patients with breast cancer.
Cancer Imaging Department, Molecular Imaging.
-Mammographic compressive force measurements as a measure of
breast density.
Cancer Imaging, Radiology, in collaboration with Melbourne University.
-Generating a bank of DCIS samples and patient derived xenografts.
Research Department, Kara Britt, and Cancer Imaging, Radiology.
-SMOC Trial. A pilot surveillance study in Li Fraumeni syndrome.
FCC Peter Mac, Cancer Imaging, Radiology.
-Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast
Cancer (PIKNIC).
Breast Medical Oncology Unit PMCC, Cancer Imaging, Radiology &
Molecular Imaging.
-Retrospective audit of screening ultrasound in breast imaging at PMCC.
Cancer Imaging, Radiology.
-Sequential functional imaging for Breast Cancer – tumour
characterisation, therapy optimisation and tumour response monitoring.
Sarah Everitt, DRO & Cancer Imaging.

Dr. Stacy Moulder completed her fellowship in Hematology/Oncology at the Vanderbilt-Ingram Cancer Center, where she also obtained a Masters of Science in Clinical Investigation. She is a medical oncologist who exclusively sees breast cancer patients and has been appointed within the Breast Medical Oncology program for 10 years at MD Anderson Cancer Center, most recently as the Chief of the Section of Clinical Research. Through this appointment, she maintains a research interest in drug development with novel targeted therapies for the treatment of triple negative breast cancer, predominately as targeted therapy trials for the treatment of metastatic breast cancer or neoadjuvant trials in patients with localized, chemotherapy insensitive disease. Her research interests are focused on the mesenchymal subtype of TNBC, which includes metaplastic breast cancer, a particularly aggressive, chemotherapy refractory form of TNBC that has a high frequency of aberrations in PI3K/Akt/mTOR pathway and has demonstrated response to mTOR inhibition in combination with chemotherapy.

Dr. Seigo Nakamura gained his medical degree in 1982 from Chiba University. He started his career as general surgeon at St. Luke’s International Hospital in Tokyo, Japan after graduation. After 28-years service at St. Luke’s International Hospital, he has moved to Showa University School of Medicine. Currently, Dr. Nakamura is Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University Hospital. He is also Chairman of the Board of Directors in the Japanese Breast Cancer Society. He has dedicated himself to clinical practice and clinical trials on breast cancer. Dr. Nakamura has focused on genetic diagnosis and tailored treatment.

Dr Catherine Oakman is a clinician. She obtained her medical degree from The University of Melbourne and trained as a Medical Oncologist in Victoria, Australia. She completed her fellowship in Breast Cancer at the “Sandro Pitigliani” Medical Oncology Unit and Translational Research Unit, Hospital of Prato, Tuscany, Italy. She currently works as a Medical Oncologist at Western Health and Barwon Health, Victoria.

Jane O’Brien is a specialist oncoplastic breast cancer surgeon whose practice is exclusively confined to breast surgery. Her strong and primary focus is on the delivery of high quality clinical care, with a special interest in oncoplastic and risk reduction surgery. She currently works within a private multidisciplinary breast service in Melbourne.

Dr Jenny O’Sullivan
Jenny O’Sullivan graduated in Medicine at Sydney University in 1988. After spending several years in General Practice she commenced training as a Breast Physician at the Sydney Breast Clinic in 1996. Jenny achieved Fellowship of the Australasian Society of Breast Physicians in 2005. She moved to Auckland in 2005 where she worked at St Marks Breast Clinic, then returned to Sydney in 2008 to take up roles at Breastscreen NSW and Royal North Shore Hospital. She also works in private practice at Mater Clinic Sydney.
Jenny has extensive experience in the diagnosis and management of breast cancer as well as benign breast disorders and breast cancer risk management.
Qualifications
MB, BS
Fellow of the Australasian Society of Breast Physicians
Master of Psychological Medicine (UNSW, 2000)
Current Appointments
Staff Specialist, Area Cancer Services, Royal North Shore Hospital
(Northern Sydney Central Coast LHD) since 2010
VMO BreastScreen NSW, Sydney LHD and Sydney South West LHD since 2008
VMO Mater Clinic, North Sydney since 2015

Associate Professor Nirmala Pathmanathan, BSc (Med), MB, BS, FRCPA, MIAC

Associate Professor Nirmala Pathmanathan is an anatomical pathologist with expertise in breast diseases. She is the Director of the Westmead Breast Cancer Institute in Sydney, which is a comprehensive multidisciplinary breast cancer program covering Western Sydney. She is also the Director of the BreastScreen Program for Sydney West and the Designated/Lead Pathologist for this program. She is a Clinical Associate Professor with the University of Sydney and Conjoint Associate Professor with the University of Western Sydney. A/Prof Pathmanathan is currently a specialist breast pathologist at Douglass Hanly Moir Pathology (part time).
A/Professor Pathmanathan is the recipient and chief or principal investigator on a number of grant-funded projects and is a past executive committee member of the Australian Breast Cancer Tumour Bank. She is a Member of NBOCC Sentinel Node Biopsy Subgroup and was involved in the development of recommendations for use of Sentinel Node Biopsy in Breast Cancer. Recently, A/Professor Pathmanathan has been a steering committee member in the development and presentation of breast cancer workshops, aimed at improving the quality of breast cancer pathology and HER2 testing in several countries across the Asia Pacific Region. She sits on the Executive Committee for the Australasian Society for Breast Diseases and is a National Clinical Advisory Board Member for BreastScreen Australia. Her primary research interests are in HER2 testing, prognostic markers in ER positive breast cancer and borderline/atypical lesions of the breast.

Dr Claire Phillips is a radiation oncologist at Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne. She is a subspecialist in breast cancer and neuro-oncology and has been involved in multiple clinical trials for both of these broad areas. Claire’s particular interest is disease and phenotype-specific management of brain metastases. She is Chair of Local HER-O (TROG 16.02), an investigator-initiated study of local therapy for HER2 positive breast cancer brain oligometastases.

Dr. Pierce is a Professor with tenure of Radiation Oncology at the University of Michigan School of Medicine and Vice Provost for Academic and Faculty Affairs of the university. She has published over 160 manuscripts and book chapters and has received numerous teaching awards and international honors. She is a member of both the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford and the National Cancer Institute, NIH Breast Cancer Steering Committee. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on cardiac-sparing treatment planning, pre-clinical and clinical studies of radiation sensitizers and RT, and outcomes following radiation in BRCA1/2 mutation carriers.

Dr Chris Pyke is Associate Professor of Surgery at the University of Queensland, based at the Mater Hospital in Brisbane.
He is a former President of the Breast Surgeons Society of Australia and New Zealand (BreastSurgANZ).
His Research interests include Personalized Medicine, Oncoplastic Surgery and Quality Assurance in Breast Cancer Surgery.

Dr. P. Raghu Ram
Amongst the foremost Surgeons from South Asia, Dr. P. Raghu Ram conceived, designed & established South Asia’s FIRST free standing, purpose built and comprehensive Breast Health Centre in Hyderabad, India (KIMS-USHALAKSHMI Centre for Breast Diseases – 2007). He obtained FRCS from all four Surgical Royal Colleges in British Isles (London, Edinburgh, Glasgow & Ireland) & trained at world renowned Breast Centres in the UK. He relocated to India when his mother was diagnosed with breast cancer and within a short span of ten years (2007 – 2017), he made extraordinary contribution towards empowering people in India about the importance of early detection of breast cancer through a number of unique initiatives in addition to implementing South Asia’s largest population based Breast Cancer Screening Programme. Equally, he has been working with missionary zeal at bringing about revolutionary changes to Breast healthcare in the Country. In 2011, Dr Raghu Ram’s proposal to establish South Asia’s FIRST dedicated Breast Surgical society (Association of Breast Surgeons of India) was seconded by Surgeons practicing breast surgery from across India. He was Founder Honorary Secretary & is currently the immediate Past President of this Association.

Dr. Raghu Ram was conferred the International Gold Medal (2013) by the Royal College of Surgeons of Edinburgh (2013) – highest Award that the Royal College bestows to Surgeons practicing outside United Kingdom & he is the youngest ever recipient of this coveted honour in 513 years history of the oldest Surgical College in the World. In recognition of his outstanding academic track record, significant social service & innovative initiatives that has transformed Breast healthcare in the region, he was conferred the prestigious Padma Shri by Hon’ble President of India (2015) making him one of the youngest Surgeons from India to have received one of the highest civilian awards of the land. He is also one of the youngest doctors from India to have been conferred the ‘Dr. B.C Roy National Award’ by Hon’ble President of India (2016) – the highest recognition that can be achieved by a doctor practicing Medicine in India.

Nick Repin is a diagnostic and interventional radiologist based near Lismore in regional NSW, Australia. His subspecialty interests include breast imaging in the context of population screening, and the roles of interventional radiology in breast disease. He is active both in public hospital and private practice, has been reading and assessing in NSW BreastScreen for 20 years, and is Designated Radiologist both for BreastScreen NSW North Coast and BreastScreen Tasmania.

Professor Bernhard Riedel, MB.ChB, FCA, FANZCA, FAHA, FASE, MMed, MBA, PhD Bernhard is the Director of the Department of Anesthesia, Perioperative and Pain Medicine at the Peter MacCallum Cancer Centre, with an honorary academic appointment at the University of Melbourne. His academic interests lie in the field of onco-anaesthesia, with his collaborative efforts investigating the role of prehabilitation prior to major surgery and the impact of the perioperative adrenergic-inflammatory response and anaesthetic technique on tumor-progression signaling as methods of improving cancer outcomes.

Dr Allison Rose MB. BS, M. MED, FRANZCR
Director, Northwestern BreastScreen
Head, The Royal Melbourne & The Women’s Hospital Breast Imaging Service Consultant Radiologist, The Royal Melbourne Hospital Associate, University of Melbourne Radiology Department.Dr Allison Rose worked at the Victorian Pilot Program for the Early Detection of Breast Cancer from 1989 under the auspice of The Royal Melbourne Hospital and became Director in 1999. In 2009 she became Head of Breast Imaging for the combined Royal Melbourne & The Women’s Hospital Breast Service & in this role she has led the team to deliver fully integrated comprehensive breast imaging across diagnostic and screening sites. She was instrumental in establishing Breast MRI & MRI guided biopsy for the service and more recently developed protocols for contrast enhanced digital mammography. Her current interests are focussed on risk based tailored breast screening and appropriate staging of diagnosed breast cancer- BreastStage.

Professor Christobel Saunders MB BS, FRCS, FRACS, FAAHMS 2017 WA Scientist of the Year is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to many clinical aspects of breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. She has performed research for >25 years evaluating the efficacy and utility of therapy for early breast cancer. In the past five years, Professor Saunders has published 100 peer-reviewed journal articles (including two in The Lancet), six letters to the editor/editorials, two research reports, three book chapters and one book. She was recently awarded a $9m dollar grant to undertake research into value based healthcare in WA. She sits on boards of a number of cancer organisations including the ANZ Breast Cancer Trials Group and is President of the Breast Surgical Society of Australia and New Zealand; and is closely involved in strategic planning and management of cancer services in Western Australia as author of the WA Health Cancer Services Framework and as first A/Director, WA Cancer and Palliative Care Network , and past President of the Cancer Council WA; and nationally as past Advisory Council member of organisations such as Cancer Australia.

Ego Seeman BSc MBBS FRACP MD AM
Ego Seeman has worked in the field of bone biology for 35 years studying the epidemiology, pathogenesis and treatment of bone fragility. He emphasized the role of growth as a forerunner of bone frailty in old age, emphasized the role of cortical and trabecular microstructural deterioration as a cause of bone fragility, and signaled that fractures in both sexes is a public health problem. He has contributed to studies of many drugs used today. He has over 360 publications.
He is past President of the ANZBMS, Editor of Progress in Osteoporosis, and Associate Editor of Osteoporosis International. His work has been recognized by awards including the Bartter Award from the American Soc, Bone Mineral Research 2002, Austin Hospital Medical Research Foundation Distinguished Scientist Award 2008, International Osteoporosis Foundation Medal of Achievement 2009, the Haddad Award from the International Bone mineral society 2013, Inaugural Career Achievement Award, Aust. New Zealand Bone Mineral Society 2014, and Member Order of Australia 2016.

Clair Shadbolt MBChB FRANZCR
Consultant Radiologist Royal Women’s
Hospital & Peter MacCallum Cancer Centre
Clair obtained her medical degree from Otago University
and radiology training at Auckland Hospital in New Zealand, spending her final registrar year in London at the Hammersmith and Royal Marsden Hospitals.
Clair then completed two years of MRI Fellowship in the USA, at the University of California, Irvine and Memorial Sloan-Kettering Cancer Centre in New York.
Clair has sub-specialty interest in Women’s imaging and is a Staff Radiologist and Director of Training at The Women’s Hospital and Lead Breast MRI Radiologist at Peter MacCallum Cancer Centre in Melbourne. She is the course convenor of the Melbourne Pelvic MRI Intensive course and on faculty for the Melbourne Breast MRI Intensive course.
Clair has authored several peer-reviewed journal articles and presented at local, national and international scientific meetings.

Kerry Shanahan has worked as a Breast Care Clinical Nurse Consultant at the Royal Melbourne Hospital for more than 15 years.
Particular areas of interest are survivorship care in early breast cancer & enhancing care in metastatic breast cancer.
She has a role on a number of committees which are involved in initiating new innovations in breast service provision. Kerry has been a member of the organising committee of previous Breast Care Nurse conferences in Melbourne.

Dr Catherine Shannon is Senior Medical Oncologist at the Mater Cancer Care Centre, Director of Medical Oncology Clinical trials unit, a member of Mater Research’s Clinical Research group and Senior Lecturer at the University of Queensland, Brisbane, Australia. She is the Principal or Co-investigator on a number of Phase I, II and III clinical trials in breast and gynaecological cancer. She is currently on the Executive Committee of the Australian Society of Breast Disease and member of the Breast cancer advisory panel for Cancer Australia.
Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field. Dr Shannon recently started a private practice at the Mater Cancer Care Centre in South Brisbane. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon acted as Chair at the committee for writing endocrine therapy guidelines for the management of advanced breast cancer.

Lisa is a Breast Care Nurse Coordinator at The Peter Mac Callum Cancer Centre and has over 18 years’ experience working at Peter Mac. She has predominantly worked in the breast cancer area with 10 years’ experience working in Nursing and Supportive Care Research.
Lisa has been a member of the organising committee of the past three Breast Care Nurse Conferences held in Melbourne.

Alito Soares (Lito)
(Doctor – General Surgeon) from Timorense.
Lives in Dili Timor Leste.
Married with 3 children.
Works at Hospital Nacional Guido Valadares as Director of Department of Surgery.
Involved in teaching a Family Medicine Program (FMPs/intent) and Post Grade Diploma in Surgery.
Chairperson of National Breast Cancer Control in Timor Leste.

Danielle Spence is the Director of Advocacy, Policy and Programs at Breast Cancer Network Australia, the peak national consumer advocacy organisation for Australians affected by breast cancer. She has a background in oncology nursing and has managed a number of supportive care projects for women with breast cancer working collaboratively with consumers, government, health professionals and other cancer care stakeholders. She has served on numerous cancer advisory groups and is a member of the ABC Global Alliance Executive Committee that seeks to improve and extend the lives of patients living with metastatic breast cancer worldwide.

Associate Professor of Surgical Oncology
The University of Sydney, Northern Clinical School
Breast and Surgical Oncology at the Poche Centre
Melanoma Institute Australia
Mater Hospital North Sydney
Royal North Shore Hospital, Northern Sydney Cancer Centre
Immediate Past President, BreastSurgANZ

Dr Lesley Stafford BA(Hons) MA(Psych) MPsych(Clin) PhD is the Head of Clinical Psychology at the Royal Women’s Hospital. Her role at the Women’s has included establishing both a clinical psycho-oncology service and a formal psycho-oncology research program. Dr Stafford initially studied in South Africa before completing further clinical training and a PhD at the University of Melbourne, where she is a Senior Lecturer. Her research interests are in the psychological aspects of cancer, specifically, developing sustainable interventions to optimize the quality of life of those affected by cancer. Her clinical work is predominantly with women with breast cancer and those at high risk of developing cancer.

Dr Norman Swan FRCP, DCH, MD (Hon Causa)

Dr Norman Swan hosts The Health Report on the ABC’s Radio National, and Tonic on ABC News24 (Television). The Health Report is the world’s longest running health programme in the English speaking world and Norman has won many awards for his work including Australia’s top prize for journalism, the Gold Walkley. He was only the third person to be awarded the prestigious medal of the Australian Academy of Science and was given an honorary MD by the University of Sydney on its 150th anniversary.
Norman trained in medicine in Scotland and paediatrics in London and Sydney before joining the ABC and has hosted many other programmes on radio and television.
 He was the medical host on Channel Ten’s Biggest Loser for six seasons and in September 2015 made a Four Corners on waste in the healthcare system. Norman created, wrote and narrated Invisible Enemies, a four part series on disease and civilisation for Channel 4 UK and broadcast in 27 countries.
He has consulted to the World Health Organisation and co chaired a global meeting of health ministers in Bamako West Africa focused on evidence based policy and priorities in health research. He has been the Australian correspondent for both the Journal of the American Medical Association (JAMA) and the British Medical Journal (BMJ).
Norman is also co-founder of Tonic Health Media, an integrated health television channel and production company which has over 15 million viewers per month.

Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer. In October 2018 he became Chief of Breast Surgery and Co-Director of the Dan L. Duncan Breast Center at Baylor College of Medicine, Houston Texas.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 24 PhD or research MD students and currently has 2 students completing PhDs. The impact of over 300 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research and leadership positions in the South West Oncology Group and Translational Breast Cancer Research Consortium.

Dean Trotter is the head of the Plastic & Reconstructive Surgery unit at the Women’s Hospital, Melbourne and clinical lead of the breast reconstruction service at the Royal Melbourne Hospital. He completed a fellowship in microsurgery at the St Andrew’s Centre in the UK in 2009-10 and has performed over 850 breast reconstructions in both public and private practice since his return to Melbourne in 2011. Dean has a sub-speciality interest in breast reconstruction following risk-reduction mastectomy.

Dr. Janice Tsang is a Specialist in Medical Oncology and the Hon. Clinical Assistant Professor at the Li Ka Shing Faculty of Medicine, The University of Hong Kong. Her research interests lie mainly in Breast Oncology, Geriatric Oncology, Translational Research and Psycho-Oncology. Being the first female academic medical oncologist at The University of Hong Kong, Dr. Tsang was awarded the 2014 Hong Kong Ten Outstanding Young Persons Award, and the 2012 Hong Kong City Lady Award (Professional & Academic Category) as the only medical professional receiving this award for the year. She was also the winner of the Psychosocial Oncology Young Investigator Award at the 16th Hong Kong International Cancer Congress & 6th Annual Meeting of Centre for Cancer Research in 2009 and was bestowed the Faculty Teaching Medal in 2012, and the Outstanding Teaching Award (Team Award) for Medical Humanities in 2013 in recognition of her being one of the pioneers in incorporating Medical Humanities in the formal medical curriculum. She has conducted over 80 clinical trials including local, regional and international multi-centred clinical trials, and has been serving as Chairperson for Data Monitoring Committee, Steering Committee Members for major multi-centred clinical trials, and various International and Regional Advisory Boards. She is a key opinion leader in breast oncology both locally and regionally. She is also the Founding Convenor of the Hong Kong Breast Oncology Group (HKBOG) which is now a member of the “Breast International Group” (BIG), being the third Asian member after Japan and Taiwan. She is also appointed as Chair of the CTRG Audit Committee for the National Cancer Institute in 2017, and a member of the International Society of Geriatric Oncology (SIOG), serving as co-track chair for translational research in SIOG.
Dr. Tsang is currently the Member of the Specialty Board of Medical Oncology and used to be the Programme Director for Medical Oncology in the Hong Kong Island at the Hong Kong College of Physicians, a member of the Co-ordinating Committee (CoC) for Medical Oncology at the Hospital Authority, and the Deputy Chairperson for the Institutional Review Board for the Hong Kong West Cluster/ HKU (2012-2016), She was the Director of Cancer Centre at the Queen Mary Hospital (2014-2015). She has various appointments in different professional bodies such as the Honorary Advisor for various cancer self-help groups including the Hong Kong Christian Cancer Care Association, Hong Kong Caner Fund etc. Furthermore, she serves as a member of the Social Welfare Advisory Committee and the Rehabilitation Advisory Committee at the HKSAR. She is also the Founding Vice President of the Hong Kong Women Doctors Association, and Immediate Past Warden of the Starr Hall at The University of Hong Kong.

Josese Turagava
I am the head of department for Surgery at the Colonial War Memorial Hospital in Suva, Fiji.
General Surgeon and Paediatric Surgeon for Fiji since 2012.
Interest in Breast Cancer surgery since 2012. Fiji has over 200 new cases breast cancer per year and our hospital looks after 2/3 of the workload.
Only 40 – 60 cases finally have breast cancer treatment.
We do not have much modalities of treatment and we improvise within our limited resources to get the best outcomes for our patients.

Jane Turner has worked for 25 years as a consultation-liaison psychiatrist in oncology. She has extensive experience in the development and implementation of clinical practice guidelines. She was an Investigator on the successful Australian multi-site trial of a manual-based intervention for fear of cancer recurrence.
She is President-Elect of the International Psycho-Oncology Society (IPOS) and chairs the IPOS-WHO committee which aims to promote psychosocial care in low and middle-income countries. In this capacity she is engaged in initiatives to embed psychosocial care in clinical practice and national cancer control plans.

Linda T. Vahdat, MD MBA
Linda T. Vahdat, MD, MBA is the Chief of Cancer Services and Head of the Department of Hematology/ Oncology at the Memorial Sloan Kettering Cancer Center (MSK) -Norwalk Hospital Partnership. She is a Member of the Breast Medicine Service at MSK and a Professor of Medicine at Weill Cornell Medicine in NYC.
Dr. Vahdat earned her undergraduate degree from Barnard College/Columbia University in New York City and completed her medical degree from Mount Sinai School of Medicine. She remained at Mount Sinai for her residency training in Internal Medicine, after which she completed fellowship training in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center (MSKCC). In 2014 completed a Master’s degree in Business Administration at the Sloan School of Management at the Massachusetts Institute of Technology. She found it a perfect complement to her research activities since the program focused on management, operations, entrepreneurship and data analytics.
Although a translational breast cancer medical oncologist by training, Dr. Vahdat’s expertise is in drug development and has been involved in the identification, conceptualization, design and conduct of Phase 0 through III clinical trials of new therapies in high-risk adjuvant and metastatic breast cancer patients since 1994. She has led 2 separate drug development efforts that led to the FDA approval 2 drugs active in metastatic breast cancer and her team has taken the lead for at least 2 other drugs that have a high probability of success, both in triple negative breast cancer. She founded the Triple Negative Breast Cancer Clinic at Weill Cornell, the second in the US, in 2014. She then founded the first one in Connecticut at Norwalk Hospital, as a part of the Western Connecticut Health Network- an organization responsible for one million lives in CT. Other significant research interests include elucidation of the process of metastases and side effects of therapy such as chemotherapy induced peripheral neuropathy. She is motivated to integrate new technology into translational medicine and has a number of collaborations both at Cornell Bio-engineering and at MIT she hopes will change how we view and treat cancer. She has also been actively involved and has held several leadership positions in the American Society of Clinical Oncology including Co-Chair of ASCO Breast Cancer Symposium. Dr. Vahdat was also on the Executive Board of Cancer Care from 2006 until 2012.

Dr Adam Walker’s research program investigates the role of neuroinflammation in psychiatric illness and cognitive function. Adam completed his PhD at the University of Newcastle and undertook a successful postdoctoral fellowship at the prestigious MD Anderson Cancer Center, USA. Now located at Monash Institute of Pharmaceutical Sciences, Adam is invested in novel drug design and repurposing safe available anti-inflammatories and other drugs to combat breast cancer-associated cognitive impairment. As a National Breast Cancer Foundation research fellow, Adam is applying his expertise in neuroinflammation to identify novel mechanisms and treatments for chronic central nervous system (CNS)-related side-effects of cancer and cancer treatment. These mechanisms include neuroinflammation, the IDO-kynurenine pathway and blood-to-brain transport mechanisms. To accomplish this he uses syngenic, orthotpic mouse models of breast cancer metastasis to explore bidirectional communication between the brain and tumour. He has pioneered the repurposing of novel drugs and supplements (aspirin, ketamine and leucine) to treat inflammation and cancer-associated cognitive impairment and depression.

Associate Professor Sanjay Warrier is a dedicated and compassionate Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW.
He completed his undergraduate medical training at the University of New South Wales in 2002 with post fellowship training specialising in breast oncology and oncoplastic surgery within Prince of Wales and the Royal Prince Alfred Hospital networks.
In 2013, Sanjay’s work on Hedgehog signaling, in collaboration with Garvan Institute, won the Patron’s Prize at RPAH for best scientific oral presentation.
He is an Associate Professor at the University of Sydney with the Royal Prince Alfred Institute of Academic Surgery and is the lead researcher at the Institute with the goal to improve patient outcomes through the application of the latest research and innovative technology available both in Australia and around the world.
In 2017 Sanjay was the pioneer surgeon in Australia of the SPY Elite System in his theatres. This technology is the most advanced fluorescent imaging system in the world to accurately identify healthy blood flow around remaining tissue, assisting with the decisions for immediate breast reconstructive surgery following breast-gland removal.
A/Prof Warrier is the Course Co-Founder and Co-Coordinator of the Oncoplastic Masters Course at the University of Sydney.
Sanjay is a Board member of the Sydney Breast Cancer Foundation, a role that he is honoured to hold.
He is the current Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training of future breast surgeons in Australia and New Zealand, and the current Site Director of Surgical Training at RPAH.
Sanjay is passionate about patient care, teaching, research and in the past year has presented at various national and international conferences.

Associate Professor Nicholas Wilcken MB BS, PhD, FRACP,
Nicholas Wilcken is Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, Senior Staff Specialist at Nepean Hospital, and Associate Professor of Medicine, University of Sydney, Australia.
Medical oncology training was at Royal Prince Alfred Hospital, Sydney, followed by a PhD in breast cancer cell cycle control at the Garvan Institute, Sydney.
His clinical interests are in breast cancer and colo-rectal cancer. Research interests include translational oncology, systematic reviews and breast cancer clinical trials.
He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group and Chair of the ANZ Breast Cancer Trials Group, Scientific Advisory Committee. He has been an invited expert panel member for the last two St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.

Clinical Associate Professor Elizabeth Jane Wylie
Head of Department Radiology, Royal Perth Hospital
Medical Director, BreastScreen WA
Dr Wylie trained in medicine at the University of Western Australia. Liz completed her resident years at Royal Perth Hospital and trained in radiology at Royal Perth Hospital. Liz spent two years in the United Kingdom undertaking post fellowship training.
Since 1990, Liz has worked as a consultant radiologist at Royal Perth Hospital and BreastScreen WA. Liz has been the Medical Director of BreastScreen WA since March 2000. Liz has been the Head of the Diagnostic & Interventional Radiology Department at Royal Perth Hospital since 2007. Liz is a Clinical Associate Professor with the Schools of Surgery and Medicine for the University of Western Australia.
Liz has an abiding interest in breast imaging, and population screening, she has been an author in a number of papers, and presents to national meetings on a regular basis.

Mei Ling Yap is a staff specialist radiation oncologist at Liverpool and Macarthur Cancer Therapy Centres, Sydney. She is a conjoint senior lecturer at UNSW Sydney and Western Sydney University and an adjunct senior lecturer at University of Sydney. She undertook a clinical research fellowship at the Princess Margaret Cancer Centre, Toronto, from 2011-2013, which included sub-specialisation in radiotherapy for breast cancer.
She is the co-chair of the Asia Pacific Radiation Oncology Special Interest Group (APROSIG) RANZCR-FRO, which supports the safe and sustainable development of radiotherapy services in low and middle income countries in our region. She was selected to be a Union for International Cancer Control (UICC) Young Cancer Leader in 2015. She is currently undertaking a health services research PHD exploring inequities in access to cancer treatment.

Dr Belinda Yeo (FRACP, MD, MBBS, BA)
Belinda Yeo is jointly appointed to the Austin Hospital as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays. She is a clinical trial investigator and continues her translational research at the ONJ Centre investigating improving personalization and minimising toxicities for patients with breast cancer.

Yvonne Zissiadis trained as a Radiation Oncologist at the Peter MaCallum Cancer Institute, Melbourne, Australia. This was followed by a Fellowship in Breast Cancer at the Breast Cancer Institute of Australia, NSW. She then commenced work as a radiation oncologist at the Prince of Wales Hospital, Randwick, NSW. In 1999, Yvonne completed a fellowship at the Massachusetts General Hospital and then returned to her home town of Perth, Western Australia to take up the position of radiation oncologist at Royal Perth Hospital and Perth Radiation Oncology. This then became Fiona Stanley Hospital and Genesiscare WA.
Her other activities include membership of the RANZCR Education and Training committee, RANZCR Radiation Oncology Research Committee, TROG, BTG, ASTRO and ESTRO. She holds conjoint lectureship positions with the University of Western Australia and Edith Cowen University. From 2015, she has held the position of President of the Australasian Society of Breast Disease. She has contributed to the organisation of a number of conferences, teaching courses and workshops as well as registrar teaching.